Evidence map›Paper›PMID 38298165›Full record

ArticleThe Journal of clinical endocrinology and metabolism2024

Body Mass Index and Uterine Fibroid Development: A Prospective Study.

Quaker E Harmon, Stacy Patchel, Sheri Denslow, Ganesa Wegienka, Donna D Baird

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Body Mass Index and Uterine Fibroid Development: A Prospective Study.The Journal of clinical endocrinology and metabolism · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Quaker E HarmonEpidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC 27709, USA.ORCID 0000-0002-5866-848X
Stacy PatchelWestat, Public Health Practice, Durham, NC 27713, USA.
Sheri DenslowSocial & Scientific Systems Inc., a DLH Holdings Company, Durham, NC 27703, USA.
Ganesa WegienkaDepartment of Public Health Sciences, Henry Ford Health, Detroit, MI 48202, USA.
Donna D BairdEpidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC 27709, USA.
National Institute of Environmental Health Sciences · USHenry Ford Health System · USSocial and Scientific Systems (United States) · USWestat (United States) · US

Funding

Uterine LeiomyomasZIAES049013 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JUKIC, ANNE MARIE · 2009 to 2025
$14.7M
Translational Research Support CoreP30ES036084 · NIEHS · WAYNE STATE UNIVERSITY · PI Melissa A Runge-Morris · 2024 to 2026
$5.2M
American Recovery and Reinvestment ActIntramural Research Program of the National Institutes of HealthNational Institutes of Health researchNIEHS NIH HHS P30 ES036084NIEHS NIH HHS ZIAES09013
6 · The paper itself

Abstract

objectiveFibroids are hormonally dependent uterine tumors. The literature on adiposity and fibroid prevalence is inconsistent. Previous work usually combined all those with a body mass index (BMI) ≥30 kg/m2 into a single category and relied on clinically diagnosed fibroids, which misclassifies the many women with undiagnosed fibroids. We used a prospective cohort design with periodic ultrasound screening to investigate associations between repeated measures of BMI and fibroid incidence and growth assessed at each follow-up ultrasound.

methodsThe Study of Environment, Lifestyle & Fibroids followed 1693 Black/African American women, ages 23 to 35 years from Detroit, Michigan, with ultrasound every 20 months for 5 years. Measured height and repeated weight measures were used to calculate BMI. Fibroid incidence was modeled using Cox models among those who were fibroid free at the enrollment ultrasound. Fibroid growth was estimated for individual fibroids matched across visits as the difference in log-volume between visits and was modeled using linear mixed models. All models used time-varying BMI and adjusted for time-varying covariates.

resultsCompared with BMI <25 kg/m2, those with BMI 30 to <35 kg/m2 had increased fibroid incidence (adjusted hazard ratio, 1.37; 95% CI, 0.96-1.94), those with BMI ≥40 kg/m2 had reduced incidence (adjusted hazard ratio, 0.61; 95% CI, 0.41-0.90). Fibroid growth had mostly small magnitude associations with BMI.

conclusionBMI has a nonlinear association with fibroid incidence, which could be driven by effects of BMI on inflammation and reproductive hormones. More detailed measures of visceral and subcutaneous adiposity and their effects on hormones, DNA damage, and cell death are needed.

Indexed as

Body Mass IndexLeiomyomaUterine NeoplasmsAdiposityAdultBlack or African AmericanFemaleFollow-Up StudiesHumansIncidenceMichiganObesityProspective StudiesRisk FactorsUltrasonographyYoung Adultbody mass indexuterine fibroiduterine leiomyoma

Identifiers

PMID38298165
PMCPMC11479715
OpenAlexW4391446717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.